The green cluster is composed of targeted therapy, immunotherapy, clinical trial, ovarian cancer, small cell lung cancer, triple-negative breast cancer, bladder cancer, trop2, urothelial carcinoma, sacituzumab govitecan, non-small cell lung cancer, apoptosis, dll3, enfortumab vedotin, and biomarker et al. This evidence concerns the gene TACSTD2 and urinary bladder cancer.